XTX-202 is under clinical development by Xilio Therapeutics and currently in Phase II for Squamous Cell Carcinoma. According to GlobalData, Phase II drugs for Squamous Cell Carcinoma have a 26% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how XTX-202’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

XTX-202 overview

XTX-202 is under development for the treatment of advanced solid tumors including metastatic renal cell carcinoma, ovarian cancer, non-small cell lung cancer, squamous cell skin carcinoma and metastatic melanoma. The drug candidate targets IL2 cytokine. The drug candidates are based on Aklusion and Switchblade platform technology. It is administered through intravenous route.

Xilio Therapeutics overview

Xilio Therapeutics is a biotechnology company that discovers and develops immuno-oncology therapeutics for the treatment of lung cancer. Xilio Therapeutics is headquartered in Waltham, Massachusetts, the US.

For a complete picture of XTX-202’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.